Related references
Note: Only part of the references are listed.Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study
Se Hwa Kim et al.
BONE (2021)
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications
Leanne Teoh et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis
Akanksha Srivastava et al.
SUPPORTIVE CARE IN CANCER (2021)
Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study
J. Everts-Graber et al.
BONE (2021)
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
Hiroaki Ikesue et al.
SUPPORTIVE CARE IN CANCER (2021)
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Hiroaki Ikesue et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis
Kazumitsu Aoki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2021)
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
Peter Burckhardt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
Vera Ehrenstein et al.
CANCER (2021)
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
Lianghai Jiang et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)
Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases
Anna Yuan et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2020)
Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed
Serge Ferrari et al.
BONE (2020)
Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals
Reddy Neha et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2020)
Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review
Camilla Ottesen et al.
HELIYON (2020)
Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw
Sun-Young Jung et al.
ORAL DISEASES (2019)
Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
A comparison of the cone beam computed tomography (CBCT) findings in medication-related osteonecrosis of the jaws (MRONJ) related to denosumab vs. bisphosphonates: an observational pilot study
Sarina E.C. Pichardo et al.
Oral Surgery Oral Medicine Oral Pathology Oral Radiology (2019)
Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study
T. Hasegawa et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab
Tine Loyson et al.
ACTA CLINICA BELGICA (2018)
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis
P. J. Voss et al.
ODONTOLOGY (2018)
Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab
Noam Yarom et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2018)
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
J. Chang et al.
CURRENT OSTEOPOROSIS REPORTS (2018)
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review
Suad Aljohani et al.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2017)
Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users
P. A. Eiken et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Drug-induced osteonecrosis of the jaw: the state of the art
A. Fassio et al.
REUMATISMO (2017)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Robert A. Adler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Osteonecrosis of the Jaw in Sweden Associated With the Oral Use of Bisphosphonate
Mattias Ulmner et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2014)
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update
Salvatore L. Ruggiero et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2014)
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population
T. -C. Lin et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Conservative management of bisphosphonate-related osteonecrosis of the jaws: Staging and treatment outcomes
Mark A. Lerman et al.
ORAL ONCOLOGY (2013)
Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis
Patricia Tennis et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
Aliya A. Khan et al.
JOURNAL OF RHEUMATOLOGY (2011)
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid Data from the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly clinical trials program
John T. Grbic et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2010)
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-2009 Update
Salvatore L. Ruggiero et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2009)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Share Paper
